OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell, Alex Blanckley, Helen Boldon, et al.
Nature Reviews Drug Discovery (2012) Vol. 11, Iss. 3, pp. 191-200
Closed Access | Times Cited: 1771

Showing 1-25 of 1771 citing articles:

Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom, Francesco Iorio, Patrick A. Eyers, et al.
Nature Reviews Drug Discovery (2018) Vol. 18, Iss. 1, pp. 41-58
Closed Access | Times Cited: 3671

Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanas G. Atanasov, Birgit Waltenberger, Eva‐Maria Pferschy‐Wenzig, et al.
Biotechnology Advances (2015) Vol. 33, Iss. 8, pp. 1582-1614
Open Access | Times Cited: 2306

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
David Cook, Dearg S. Brown, Robert Alexander, et al.
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 6, pp. 419-431
Closed Access | Times Cited: 1224

Organs-on-chips at the frontiers of drug discovery
Eric W. Esch, Anthony Bahinski, Dongeun Huh
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 4, pp. 248-260
Open Access | Times Cited: 1058

The Current State of Peptide Drug Discovery: Back to the Future?
Antoine Henninot, James C. Collins, John M. Nuss
Journal of Medicinal Chemistry (2017) Vol. 61, Iss. 4, pp. 1382-1414
Closed Access | Times Cited: 939

Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Péter Csermely, Tamás Korcsmáros, Huba Kiss, et al.
Pharmacology & Therapeutics (2013) Vol. 138, Iss. 3, pp. 333-408
Open Access | Times Cited: 845

An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles
Marcus Baumann, Ian R. Baxendale
Beilstein Journal of Organic Chemistry (2013) Vol. 9, pp. 2265-2319
Open Access | Times Cited: 755

Organs-on-chips: into the next decade
Lucie A. Low, Christine L. Mummery, Brian R. Berridge, et al.
Nature Reviews Drug Discovery (2020) Vol. 20, Iss. 5, pp. 345-361
Open Access | Times Cited: 685

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
B.C. Doak, Björn Over, Fabrizio Giordanetto, et al.
Chemistry & Biology (2014) Vol. 21, Iss. 9, pp. 1115-1142
Open Access | Times Cited: 672

Artificial intelligence in drug development: present status and future prospects
Kit‐Kay Mak, Mallikarjuna Rao Pichika
Drug Discovery Today (2018) Vol. 24, Iss. 3, pp. 773-780
Closed Access | Times Cited: 671

Are Ideas Getting Harder to Find?
Nicholas Bloom, Charles I. Jones, John Van Reenen, et al.
American Economic Review (2020) Vol. 110, Iss. 4, pp. 1104-1144
Open Access | Times Cited: 654

Automating drug discovery
Gisbert Schneider
Nature Reviews Drug Discovery (2017) Vol. 17, Iss. 2, pp. 97-113
Open Access | Times Cited: 651

Validating therapeutic targets through human genetics
Robert M. Plenge, Edward M. Scolnick, David Altshuler
Nature Reviews Drug Discovery (2013) Vol. 12, Iss. 8, pp. 581-594
Closed Access | Times Cited: 648

Network pharmacology: curing causal mechanisms instead of treating symptoms
Cristian Nogales, Zeinab M. Mamdouh, Markus List, et al.
Trends in Pharmacological Sciences (2021) Vol. 43, Iss. 2, pp. 136-150
Open Access | Times Cited: 642

Microengineered physiological biomimicry: Organs-on-Chips
Dongeun Huh, Yu‐suke Torisawa, Geraldine A. Hamilton, et al.
Lab on a Chip (2012) Vol. 12, Iss. 12, pp. 2156-2156
Closed Access | Times Cited: 630

Can you teach old drugs new tricks?
Nicola Nosengo
Nature (2016) Vol. 534, Iss. 7607, pp. 314-316
Open Access | Times Cited: 622

Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Miriam Góngora‐Benítez, Judit Tulla‐Puche, Fernando Alberício
Chemical Reviews (2013) Vol. 114, Iss. 2, pp. 901-926
Closed Access | Times Cited: 555

Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
Fabrizio Giordanetto, Jan Kihlberg
Journal of Medicinal Chemistry (2013) Vol. 57, Iss. 2, pp. 278-295
Closed Access | Times Cited: 510

The High Cost of Prescription Drugs in the United States
Aaron S. Kesselheim, Jerry Avorn, Ameet Sarpatwari
JAMA (2016) Vol. 316, Iss. 8, pp. 858-858
Closed Access | Times Cited: 510

Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng Fu, Minru Liao, Rui Qin, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 474

The discovery of first-in-class drugs: origins and evolution
Jörg Eder, Richard Sedrani, Christian Wiesmann
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 8, pp. 577-587
Closed Access | Times Cited: 467

Phenotypic screening in cancer drug discovery — past, present and future
John G. Moffat, Joachim Rudolph, David Bailey
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 8, pp. 588-602
Closed Access | Times Cited: 458

Artificial Intelligence for Clinical Trial Design
Stefan Harrer, Pratik Shah, Bhavna Antony, et al.
Trends in Pharmacological Sciences (2019) Vol. 40, Iss. 8, pp. 577-591
Open Access | Times Cited: 458

Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Daniel Himmelstein, Antoine Lizée, Christine Hessler, et al.
eLife (2017) Vol. 6
Open Access | Times Cited: 446

Page 1 - Next Page

Scroll to top